Krishnansu Sujata Tewari MD

Gynecologic Oncology

Professor & Gynecologic Oncologist, Director of the Division of Gynecologic Oncology

The City Tower333 City Blvd, West - Suite 1400Orange, CA 92868
Phone+1 714-456-8020
Fax+1 714-456-6632

Dr. Tewari is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tewari's full profile Already have an account?

Summary

Dr. Krishnansu Tewari is an obstetrician/gynecologist in Orange, CA and is affiliated with multiple hospitals in the area, including St. Joseph Hospital Orange, UCI Medical Center, Long Beach Medical Center, Los Alamitos Medical Center, Saddleback Medical Center, MemorialCare, Orange Coast Memorial Medical Center, and St. Jude Medical Center. He received his medical degree from University of California, Irvine, School of Medicine and has been in practice 27 years. He specializes in gynecologic oncology and is experienced in fallopian tube carcinoma, hysterectomy, gynecologic oncology, cytoreductive surgery for ovarian cancer and advanced surface peritoneal malignancies, and robotic surgery for endometrial cancer.

Education & Training

Harvard T.H. Chan School of Public HealthCertificate of Participation, Leadership Course for Academic Physicians in New Director Roles, 2018 - 2018
University of California (Irvine)Fellowship, Gynecologic Oncology, 1998 - 2002
University of California (Irvine)Residency, Obstetrics and Gynecology, 1994 - 1998
University of California, Irvine, School of MedicineClass of 1994
University of California, BerkeleyB.S., Molecular Biology, 1983 - 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1996 - 2027
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2015-2016
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:San Diego Area Castle Connolly, 2013

Clinical Trials

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
TERMINATED
PHASE2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
COMPLETED
PHASE3

Publications & Presentations

PubMed

Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
Lindsay M Kuroki, Danielle M Enserro, Heather A Lankes, Kyle C Strickland, Rebecca Previs
Gynecologic Oncology. 2026-07-01
Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E tr...
Alex A Francoeur, Su-Ying Liang, Brittany File, Eunji Choi, Max Brameld
Gynecologic Oncology Reports. 2026-04-01
Eradicating cervical cancer in the poorest regions of the world.
Courtney Fant, Krishnansu Tewari
Current Opinion in Obstetrics & Gynecology. 2026-02-01

Journal Articles

Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: A phase III NRG Oncology/Gynecologic Oncology Gro...
Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O�Malley DM, Robiso..., J Clin Oncol, 1/5/2018
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: A NRG Oncology/Gynecologic Oncology Group 182 Study
Horowitz NS, Maxwell LG, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS,..., Gynecol Oncol, 1/1/2018
Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: A NRG Oncology/Gynecologic Oncology Group Study
Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casedei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J..., Clin Cancer Res, 1/1/2018

Books/Book Chapters

University of California, Obstetrics & Gynecology, Womens Health Review
Chapter: Invasive Cervical Cancer
Tewari KS, Monk BJEditors: DiSaia PJ.2011
DiSaia & Creasmans Clinical Gynecologic Oncology
Chapter: Cancer in Pregnancy
Tewari KSEditors: McMeekin SD, Mutch.Edition 8th,2011
DiSaia & Creasmans Clinical Gynecologic Oncology
Chapter: Invasive Cervical Cancer
Tewari KS, Monk BJEditors: McMeekin SD, Mutch.Edition 8th,2011

Abstracts/Posters

Final protocol-specified overall survival and updated toxicity analysis in the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cer...
Tewari KS, Sill MW, Long HJ III, Penson RT, Huang HQ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael H, Monk BJ, Annual Meeting of the European Society of Medical Oncology, Madrid, Spain, 1/26/2014
Impact of race, socioeconomic status, and the health system on the treatment of advanced-stage ovarian caner in California
Long BJ, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE, 45th Annual Meeting on Women�s Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/22/2014
Use of a dedicated pulley system to reestablish continuity of the vagina with the uterus at the time of fertility-preserving robotic assisted laparoscopic radical trac...
Brueseke TJ, Tewari KS, 45th Annual Meeting on Women�s Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/22/2014

Lectures

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in line recurr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Landmark Careers and Landmark Clinical Trials: Defining the Message for the Next Generation of Gynecologic Oncologists
1/22/2014
Refining therapeutic strategies in advanced cervical cancer: Focus on angiogenesis
Manchester Grand Hyatt Hotel, San Diego, CA - 1/7/2014

Other

Newly diagnosed with ovarian cancer? Start here. In: Special Report � Ovarian Cancer
Tewari KS, Women Magazine
1/1/2014
The highlights: Advances in screening and management of ovarian cancer � news from Annual Meetings of the Society of Gynecologic Oncology and the American Society of C...
Tewari KS, Women Magazine
1/1/2013
Supreme Court Ruling a Major Victory for Women�s Health
Tewari KS, The Female Patient
1/1/2012

Press Mentions

Data on Cervical Cancer’s Toll on Rural America “Should Be a Call to Action,” Says ExpertMarch 12th, 2025
Induction Chemotherapy in First Line Improves Survival for Locally Advanced Cervical CancerOctober 26th, 2023
Nanodrug Treatment for Ovarian Cancer Leads to 80% Survival Rate in AnimalsApril 27th, 2023